DOCSLIB.ORG

022247Orig1s000

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
022247Orig1s000 CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 022247Orig1s000 MEDICAL REVIEW(S) CLINICAL REVIEW Application Type NDA Application Number(s) 22247 Priority or Standard Standard Submit Date(s) September 26, 2012 Received Date(s) October 3, 2012 PDUFA Goal Date October 3, 2013 Division / Office DBRUP/ODE III/OND/CDER Reviewer Name(s) Marcea Whitaker, M.D. Stephen Bienz, M.D. Gerald Willett, M.D. Stephen Voss, M.D. Theresa Kehoe, M.D. Review Completion Date June 5, 2013 Established Name Conjugated estrogens/ bazedoxifene (Proposed) Trade Name Duavee Therapeutic Class Estrogen/SERM combination Applicant Wyeth Formulation(s) Coated Tablets Dosing Regimen One tablet daily (0.625/20mg, 0.45/20mg) Indication(s) 1) Treatment mod to severe vasomotor symptoms associated with menopause 2) Treatment mod to severe vulvar and vaginal atrophy associated with menopause 3) Prevention of postmenopausal osteoporosis Intended Population(s) Postmenopausal women with intact uterus Template Version: March 6, 2009 Reference ID: 3319796 Clinical Review Whitaker/Bienz/Willett/Voss/Kehoe NDA 022247 Conjugated estrogen/bazedoxifene Table of Contents 1 Recommendations/Risk Benefit Assessment............................................. 11 1.1 Recommendation on Regulatory Action ........................................................... 11 1.2 Risk Benefit Assessment.................................................................................. 12 1.3 Recommendations for Postmarket Risk Evaluation and Mitigation Strategies . 18 1.4 Recommendations for Postmarket Requirements and Commitments .............. 18 2 Introduction and Regulatory Background ................................................... 18 2.1 Product Information .......................................................................................... 18 2.2 Tables of Currently Available Treatments for Proposed Indications ................. 18 2.3 Availability of Proposed Active Ingredient in the United States ........................ 18 2.4 Important Safety Issues With Consideration to Related Drugs......................... 19 2.5 Summary of Presubmission Regulatory Activity Related to Submission .......... 21 2.6 Other Relevant Background Information .......................................................... 22 2.6.1 Formulation/Bioavailability Issue....................................................................... 22 3 Ethics and Good Clinical Practices ..................................................................... 23 3.1 Submission Quality and Integrity ...................................................................... 23 3.2 Compliance with Good Clinical Practices ......................................................... 24 3.3 Financial Disclosures........................................................................................ 25 4 Significant Efficacy/Safety Issues Related to Other Review Disciplines........... 26 4.1 Chemistry Manufacturing and Controls ............................................................ 26 4.2 Clinical Microbiology......................................................................................... 26 4.3 Preclinical Pharmacology/Toxicology ............................................................... 27 4.4 Clinical Pharmacology...................................................................................... 27 4.4.1 Mechanism of Action ........................................................................................ 27 4.4.2 Pharmacodynamics.......................................................................................... 28 4.4.3 Pharmacokinetics ............................................................................................. 28 5 Sources of Clinical Data............................................................................. 30 5.1 Tables of Studies/Clinical Trials ....................................................................... 30 5.2 Review Strategy ............................................................................................... 32 5.3 Discussion of Individual Studies/Clinical Trials................................................. 32 6 Review of Efficacy ............................................................................................ 58 6.1 Treatment of Moderate to Severe Vasomotor Symptoms................................. 58 6.1.1 Methods ..................................................................................................... 58 6.1.2 Demographics............................................................................................ 58 6.1.3 Subject Disposition..................................................................................... 60 6.1.4 Analysis of Primary Endpoint(s) ................................................................. 61 6.1.7 Subpopulations .......................................................................................... 68 6.1.8 Analysis of Clinical Information Relevant to Dosing Recommendations .... 69 6.1.9 Discussion of Persistence of Efficacy and/or Tolerance Effects................. 69 6.1.10 Additional Efficacy Issues/Analyses ............................................................ 69 6.2 Treatment of Moderate to Severe Vulvar and Vaginal Atrophy ........................ 71 6.2.1 Methods ..................................................................................................... 71 Demographics........................................................................................................ 71 2 Reference ID: 3319796 Clinical Review Whitaker/Bienz/Willett/Voss/Kehoe NDA 022247 Conjugated estrogen/bazedoxifene 6.2.3 Subject Disposition..................................................................................... 72 6.2.4 Analysis of Primary Endpoint(s) ................................................................. 74 6.2.5 Analysis of Secondary Endpoints(s) .......................................................... 79 6.2.6 Other Endpoints ............................................................................................ 80 6.2.7 Subpopulations .......................................................................................... 81 6.2.8 Analysis of Clinical Information Relevant to Dosing Recommendations .... 81 6.2.9 Discussion of Persistence of Efficacy and/or Tolerance Effects................. 82 6.2.10 Additional Efficacy Issues/Analyses ............................................................ 82 6.3 Prevention of Postmenopausal Osteoporosis................................................... 82 6.3.1 Methods ..................................................................................................... 82 6.3.1 Methods ..................................................................................................... 83 Demographics........................................................................................................ 83 Subject Disposition................................................................................................. 85 6.3.4 Analysis of Primary Endpoint: Bone Mineral Density ................................. 87 6.3.5 Analysis of Secondary Endpoints............................................................... 95 6.3.6 Other Endpoints .......................................................................................... 104 6.3.7 Subpopulations ........................................................................................ 114 6.3.8 Analysis of Clinical Information Relevant to Dosing Recommendations .. 114 6.3.9 Discussion of Persistence of Efficacy and/or Tolerance Effects............... 114 6.3.10 Additional Efficacy Issues/Analyses .......................................................... 114 6.4 Endometrial Safety – Endometrial Protection and Endometrial Polyps .......... 115 6.4.1 Study 303.................................................................................................... 115 6.4.2 Study 304.................................................................................................... 139 6.4.3 Study 3307.................................................................................................. 150 6.4.3 Combined Study Information for Endometrial Protection ............................ 155 6.4.4 Combined Study Information for Endometrial Polyps.................................. 156 7 Review of Safety ...................................................................................... 158 7.1 Methods.......................................................................................................... 162 7.1.1 Studies/Clinical Trials Used to Evaluate Safety ....................................... 162 7.1.2 Categorization of Adverse Events............................................................ 165 7.1.3 Pooling of Data Across Studies/Clinical Trials to Estimate and Compare Incidence.................................................................................................. 165 7.2 Adequacy of Safety Assessments .................................................................. 166 7.2.1 Overall Exposure at Appropriate Doses/Durations and Demographics of Target Populations................................................................................... 166 7.2.2 Explorations for Dose Response.............................................................. 166 7.2.3 Special Animal and/or In Vitro Testing ..................................................... 167 7.2.4 Routine Clinical Testing ..........................................................................
Load more

Recommended publications
  • Uterine Double-Conditional Inactivation of Smad2 and Smad3 in Mice Causes Endometrial Dysregulation, Infertility, and Uterine Cancer
    Uterine double-conditional inactivation of Smad2 and Smad3 in mice causes endometrial dysregulation, infertility, and uterine cancer Maya Krisemana,b, Diana Monsivaisa,c, Julio Agnoa, Ramya P. Masanda, Chad J. Creightond,e, and Martin M. Matzuka,c,f,g,h,1 aDepartment of Pathology and Immunology, Baylor College of Medicine, Houston, TX 77030; bReproductive Endocrinology and Infertility, Baylor College of Medicine/Texas Children’s Hospital Women’s Pavilion, Houston, TX 77030; cCenter for Drug Discovery, Baylor College of Medicine, Houston, TX 77030; dDepartment of Medicine, Baylor College of Medicine, Houston, TX 77030; eDan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030; fDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030; gDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030; and hDepartment of Pharmacology and Chemical Biology, Baylor College of Medicine, Houston, TX 77030 Contributed by Martin M. Matzuk, December 6, 2018 (sent for review April 30, 2018; reviewed by Milan K. Bagchi and Thomas E. Spencer) SMAD2 and SMAD3 are downstream proteins in the transforming in endometrial function. Notably, members of the transforming growth factor-β (TGF β) signaling pathway that translocate signals growth factor β (TGF β) family are involved in many cellular from the cell membrane to the nucleus, bind DNA, and control the processes and serve as principal regulators of numerous biological expression of target genes. While SMAD2/3 have important roles functions, including female reproduction. Previous studies have in the ovary, we do not fully understand the roles of SMAD2/3 in shown the TGF β family to have key roles in ovarian folliculo- the uterus and their implications in the reproductive system.
    [Show full text]
  • 35 Cyproterone Acetate and Ethinyl Estradiol Tablets 2 Mg/0
    PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PrCYESTRA®-35 cyproterone acetate and ethinyl estradiol tablets 2 mg/0.035 mg THERAPEUTIC CLASSIFICATION Acne Therapy Paladin Labs Inc. Date of Preparation: 100 Alexis Nihon Blvd, Suite 600 January 17, 2019 St-Laurent, Quebec H4M 2P2 Version: 6.0 Control # 223341 _____________________________________________________________________________________________ CYESTRA-35 Product Monograph Page 1 of 48 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION ....................................................................... 3 SUMMARY PRODUCT INFORMATION ............................................................................................. 3 INDICATION AND CLINICAL USE ..................................................................................................... 3 CONTRAINDICATIONS ........................................................................................................................ 3 WARNINGS AND PRECAUTIONS ....................................................................................................... 4 ADVERSE REACTIONS ....................................................................................................................... 13 DRUG INTERACTIONS ....................................................................................................................... 16 DOSAGE AND ADMINISTRATION ................................................................................................ 20 OVERDOSAGE ....................................................................................................................................
    [Show full text]
  • Estrogenic Effect Present on Pap Smear
    Estrogenic Effect Present On Pap Smear Is Claybourne hyracoid or pluralistic after baseless Nealy retrieve so beamingly? Nonharmonic and conidialmelting Maximilienafter Asclepiadean fixates her Brewster cache retrojectsharries his while demob Jose commensurately. bray some orarions neglectingly. Louie is sic An immediate and younger des when present on hpv They may ask about possible use of agents that can going the bonfire and cause may aggravate symptoms, such as soaps or perfumes. Possibly use of ovulation detection kit. Voskuil DW, Monninkhof EM, Elias SG et al. Bleeding Between Periods: Is high Cause major Alarm? The presence of abnormal cells in the cervix that may be precancerous is called cervical dysplasia. VVA in postmenopausal women, DHEA was only compared to placebo and no active comparator group was included. This separation can be initiated by a hemorrhage into the decidua basalis and cause formation of a decidual hematoma. The present and estrogens or pharmacist if no concentration should be made only studies do about des daughters have androgenic and deaths for disposal any unusual. Any recent abdominal pain in her RUQ? Pre and post menstrual spotting is characteristic. Other causes of a hypoestrogenic state include lactation, various lung cancer treatments, and use with certain medications. In some embodiments, the cell expresses ERa In some embodiments, the cell expresses ERβ. Spironolactone, an appeal time diuretic, and decreasing the testosterone dose, is either perfect antidote for fabulous hair growth, oily skin, agitation and acne. In present singly and estrogenic effect means a colposcopically directed biopsy revealed atypical nuclei or estrogenic effect present on pap smear after intravaginal.
    [Show full text]
  • Olanzapine-Induced Hyperprolactinemia: Two Case Reports
    CASE REPORT published: 29 July 2019 doi: 10.3389/fphar.2019.00846 Olanzapine-Induced Hyperprolactinemia: Two Case Reports Pedro Cabral Barata *, Mário João Santos, João Carlos Melo and Teresa Maia Departamento de Psiquiatria, Hospital Prof. Dr. Fernando da Fonseca, EPE, Amadora, Portugal Background: Hyperprolactinemia is a common consequence of treatment with antipsychotics. It is usually defined by a sustained prolactin level above the laboratory upper level of normal in conditions other than that where physiologic hyperprolactinemia is expected. Normal prolactin levels vary significantly among different laboratories and studies. Several studies indicate that olanzapine does not significantly affect serum prolactin levels in the long term, although this statement has been challenged. Aims: Our aim is to report two olanzapine-induced hyperprolactinemia cases observed in psychiatric consultations. Methods: Medical records of the patients who developed this clinical situation observed Edited by: in psychiatric consultations in the Psychiatry Department of the Prof. Dr. Fernando Angel L. Montejo, Fonseca Hospital during the year of 2017 were analyzed, complemented with a non- University of Salamanca, Spain systematic review of the literature. Reviewed by: Carlos Spuch, Results: The case reports consider two women who developed prolactin-related Instituto de Investigación Sanitaria symptoms after the initiation of olanzapine. No baseline prolactinemia was obtained, and Galicia Sur (IISGS), Spain Lucio Tremolizzo, prolactin serum levels were only evaluated after prolactin-related symptoms developed: University of Milano-Bicocca, Italy at the time of its measurement, both patients had been taking olanzapine for more *Correspondence: than 24 weeks. Hyperprolactinemia was found to be present in Case 2, whereas Case Pedro Cabral Barata 1 (a 49-year-old woman) had “normal” serum prolactin levels for premenopausal and [email protected] prolactin levels slightly above the maximum levels for postmenopausal women.
    [Show full text]
  • 1 Evidence Tables for Mastitis, Abscess and Related Conditions And
    Evidence tables for mastitis, abscess and related conditions and issues Tabulation of studies on mastitis illustrates the heterogeneity of study design, definition of mastitis, and factors investigated. Recent studies on mastitis in Western populations have been included, with some older studies of particular interest. List of tables: Table A: Incidence and treatment of Mastitis Table B: Reviews of the literature Table B1: Core Reviews Table B2: Other review sources Table B3: Further reviews Table C: Women’s experience of mastitis Tables D: Abscess Table D1: Incidence of abscess Table D2: Interventions for abscess Table E: Overabundant milk supply Table F: Chronic breast pain Table G: Mastitis and breast augmentation Table H: Alternative treatments for mastitis Table I: Physiology of mastitis during lactation Table J: Role of specific pathogens Table J1: Role of Staphylococcus aureus in mastitis Table J2: Mastitis and MRSA Table J3: MRSA mastitis and abscess case study Table J4: Role of Corynebacterium Table K: Effects on the baby Table K1: Effects of mastitis on the baby Table K2: Antibiotic treatment of women during lactation – effects on the infant Table K3: Maternal Strep B infections and effects on the baby through breastfeeding. Table L: Prevention 1 Table A: Incidence and treatment of Mastitis: Factors associated with incidence (possible risk factors); also studies of treatment experienced by women with mastitis: Author Type of Definition of Outcomes measured Results Comments date study mastitis Scott 2008 Prospective Red, tender, hot, Incidence of mastitis, 18% (95% CI 14%, 21%) had at least one 72% of women longitudinal swollen area of the reoccurrence, timing of episode of mastitis invited to take UK cohort study breast accompanied by episodes.
    [Show full text]
  • Review Article Ovariohysterectomy in the Bitch
    Hindawi Publishing Corporation Obstetrics and Gynecology International Volume 2010, Article ID 542693, 7 pages doi:10.1155/2010/542693 Review Article Ovariohysterectomy in the Bitch Djemil Bencharif, Lamia Amirat, Annabelle Garand, and Daniel Tainturier Department of Reproductive Pathology, ONIRIS: Nantes-Atlantic National College of Veterinary Medicine, Food Science and Engineering, Site de la Chantrerie, B.P:40706, 44307 Nantes Cedex, France Correspondence should be addressed to Djemil Bencharif, [email protected] Received 31 October 2009; Accepted 7 January 2010 Academic Editor: Liselotte Mettler Copyright © 2010 Djemil Bencharif et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Ovariohysterectomy is a surgical procedure widely employed in practice by vets. It is indicated in cases of pyometra, uterine tumours, or other pathologies. This procedure should only be undertaken if the bitch is in a fit state to withstand general anaesthesia. However, the procedure is contradicated if the bitch presents a generalised condition with hypothermia, dehydration, and mydriasis. Ovariohysterectomy is generally performed via the linea alba. Per-vaginal hysterectomy can also be performed in the event of uterine prolapse, if the latter cannot be reduced or if has been traumatised to such an extent that it cannot be replaced safely. Specific and nonspecific complictions can occur as hemorrhage, adherences, urinary incontinence, return to oestrus including repeat surgery. After an ovariectomy, bitches tend to put on weight, it is therefore important to inform the owner and to reduce the daily ration by 10%.
    [Show full text]
  • Review Article Ovariohysterectomy in the Bitch
    Hindawi Publishing Corporation Obstetrics and Gynecology International Volume 2010, Article ID 542693, 7 pages doi:10.1155/2010/542693 Review Article Ovariohysterectomy in the Bitch Djemil Bencharif, Lamia Amirat, Annabelle Garand, and Daniel Tainturier Department of Reproductive Pathology, ONIRIS: Nantes-Atlantic National College of Veterinary Medicine, Food Science and Engineering, Site de la Chantrerie, B.P:40706, 44307 Nantes Cedex, France Correspondence should be addressed to Djemil Bencharif, [email protected] Received 31 October 2009; Accepted 7 January 2010 Academic Editor: Liselotte Mettler Copyright © 2010 Djemil Bencharif et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Ovariohysterectomy is a surgical procedure widely employed in practice by vets. It is indicated in cases of pyometra, uterine tumours, or other pathologies. This procedure should only be undertaken if the bitch is in a fit state to withstand general anaesthesia. However, the procedure is contradicated if the bitch presents a generalised condition with hypothermia, dehydration, and mydriasis. Ovariohysterectomy is generally performed via the linea alba. Per-vaginal hysterectomy can also be performed in the event of uterine prolapse, if the latter cannot be reduced or if has been traumatised to such an extent that it cannot be replaced safely. Specific and nonspecific complictions can occur as hemorrhage, adherences, urinary incontinence, return to oestrus including repeat surgery. After an ovariectomy, bitches tend to put on weight, it is therefore important to inform the owner and to reduce the daily ration by 10%.
    [Show full text]
  • A Simultaneous Occurrence of Feline Mammary Carcinoma and Uterine Cystic Endometrial Hyperplasia in a Cat
    pISSN 2466-1384 eISSN 2466-1392 大韓獸醫學會誌 (2017) 第 57 卷 第 4 號 Korean J Vet Res(2017) 57(4) : 245~248 https://doi.org/10.14405/kjvr.2017.57.4.245 <Short Communication> A simultaneous occurrence of feline mammary carcinoma and uterine cystic endometrial hyperplasia in a cat Ji-Hyun Yoo1, Okjin Kim2,* 1Technology Service Division, National Institute of Animal Science, Rural Development Administration, Wanju 55365, Korea 2Center for Animal Resource Development, Animal Disease Research Unit, Wonkwang University, Iksan 54538, Korea (Received: July 17, 2017; Revised: October 4, 2017; Accepted: October 24, 2017) Abstract: At the time of visiting, the cat was 6-year-old female Siamese cat. The mammary mass was solid and firm and measured 2×5cm2 in greatest diameter. The uterus revealed thick uterine horn and cross sectioned wall. Histopathologically, the mammary mass revealed feline mammary carcinoma. In the uterus, cystic endometrial hyperplasia was observed. Feline leukemia virus positive reaction was detected by polymerase chain reaction. As far as we know, this is the first report of the simultaneous feline mammary carcinoma and uterine endometrial cystic hyperplasia with Feline leukemia virus infection in a cat. Keywords: Feline leukemia virus, cats, feline mammary carcinoma, uterine hyperplasia Tumors in mammary glands have been reported mainly in older female cats above 10 to 12 years [15]. Cats with mam- mary tumors are usually dead less than 1 year after the diag- nosis, and the size of tumor mass is the most significant prognostic barometer [15]. Presentation of complex cystic endometrial hyperplasia- pyometra (CEH-P) is not very common in cats.
    [Show full text]
  • Pseudoangiomatous Stromal Hyperplasia of the Breast
    Case Report / Olgu Sunumu J Breast Health 2015; 11: 148-51 DOI: 10.5152/tjbh.2015.2333 Pseudoangiomatous Stromal Hyperplasia of the Breast: Mammosonography and Elastography Findings with a Histopathological Correlation Psödoanjiomatöz Stromal Hiperplazi Bildirilen Kitlenin Mamo-Sonografi ve Elastografi Bulguları Ebru Yılmaz1, Fatma Zeynep Güngören1, Ayhan Yılmaz1, Tuğrul Örmeci1, Gonca Özgün3, Sibel Çağlar Atacan2, İsmail Sinan Duman4 1Department of Radiology, Medipol University Faculty of Medicine, İstanbul, Turkey 2Department of Radiology, Forensic Medicine Institute, İstanbul, Turkey 3Department of Pathology, Medipol University Faculty of Medicine, İstanbul, Turkey 4Clinic of Radiology, Gaziosmanpaşa Taksim Training and Research Hospital, İstanbul, Turkey ABSTRACT ÖZ Pseudoangiomatous stromal hyperplasia (PASH) is a rare benign mesenchy- Psödoanjiomatöz stromal hiperplazi (PASH), memenin benign mezenkimal mal proliferative lesion of the breast. In this study, we aimed to show a case proliferatif hastalıklarındandır. Stromal miyofibroblastların proliferasyonu of PASH with mammographic and sonographic features, which fulfill the sonucu oluşur. Tipik olarak pre ve perimenapozal kadınlarda görülür. Meme- criteria for benign lesions and to define its recently discovered elastography de ağrı şikayetiyle genel cerrahi polikliniğine başvuran kırk dokuz yaşındaki findings. A 49-year-old premenopausal female presented with breast pain in premenapozal kadın hastanın yapılan meme ultrasonografisinde (US) sağ our outpatient surgery clinic. In ultrasound
    [Show full text]
  • Med12 Gain-Of-Function Mutation Causes Leiomyomas and Genomic Instability
    Med12 gain-of-function mutation causes leiomyomas and genomic instability Priya Mittal, … , Urvashi Surti, Aleksandar Rajkovic J Clin Invest. 2015;125(8):3280-3284. https://doi.org/10.1172/JCI81534. Brief Report Genetics Uterine leiomyomas are benign tumors that can cause pain, bleeding, and infertility in some women. Mediator complex subunit 12 (MED12) exon 2 variants are associated with uterine leiomyomas; however, the causality ofM ED12 variants, their genetic mode of action, and their role in genomic instability have not been established. Here, we generated a mouse model that conditionally expresses a Med12 missense variant (c.131G>A) in the uterus and demonstrated that this alteration alone promotes uterine leiomyoma formation and hyperplasia in both WT mice and animals harboring a uterine mesenchymal cell–specific Med12 deletion. Compared with WT animals, expression of Med12 c.131G>A in conditional Med12–KO mice resulted in earlier onset of leiomyoma lesions that were also greater in size. Moreover, leiomyomatous, Med12 c.131G>A variant–expressing uteri developed chromosomal rearrangements. Together, our results show that the common human leiomyoma–associated MED12 variant can cause leiomyomas in mice via a gain of function that drives genomic instability, which is frequently observed in human leiomyomas. Find the latest version: https://jci.me/81534/pdf BRIEF REPORT The Journal of Clinical Investigation Med12 gain-of-function mutation causes leiomyomas and genomic instability Priya Mittal,1 Yong-hyun Shin,2 Svetlana A. Yatsenko,2,3 Carlos A. Castro,2 Urvashi Surti,1,2,3 and Aleksandar Rajkovic1,2,3 1Department of Human Genetics, Graduate School of Public Health, 2Department of Obstetrics, Gynecology and Reproductive Sciences, Magee-Womens Research Institute, and 3Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
    [Show full text]
  • Dysfunctional Uterine Bleeding (DUB)
    Dysfunctional Uterine Bleeding (DUB) What is Dysfunctional Uterine Bleeding (DUB) Dysfunctional uterine bleeding (DUB) is abnormal bleeding from the uterus that is not due to pregnancy or other recognizable pathology in the women’s uterus, pelvic or systemic disease. It is a functional problem of the uterus largely due to hormonal imbalance and not related to structural or anatomical problem. It is commonly present as heavy menstrual bleeding (menorrhagia). However, the doctor can only derive to a diagnosis of DUB after all other causes for abnormal and heavy menstrual bleeding in a patient have been investigated and excluded. Who gets DUB and why is it important to know Almost every woman is at risk of experience DUB in their lifetime. Dysfunctional uterine bleeding occurs most often in adolescent and in women after 40 and close to menopausal age. Studies showed that nearly 80% of heavy menstruation (i.e. menstrual blood loss >80 mls per month) is caused by DUB. Heavy menstrual bleeding may affect a woman’s health both medically and socially causing problem such as iron deficiency anaemia and social phobia or discomfort respectively. Dysfunctional uterine bleeding is the commonest cause of iron deficiency anaemia in women in the developed world and of chronic illness in developing world. It also affects productivity as almost 10 % of women absent from work due to heavy menstrual bleeding. For adolescent, heavy menstrual bleeding resulting in anaemia affects their school performance as they often feel lethargic and unable to participate in school activities too. What are other causes of abnormal menstrual bleeding? Other than DUB, the functional problem that often responsible for heavy or abnormal menstruation, there are many structural and systemic cause that need to be investigated and excluded first before DUB can be diagnosed.
    [Show full text]
  • Attleboro-1929.Pdf (14.94Mb)
    c/0m2isl JSZS . • * ' \ f - V' 'vr ' « >-f- ' > . > K T ' ' '{ .Jv, ’ •^ * u • \ s « \ * ' ‘ > ' ' » ‘ ‘ V • V > . V \ -* i '. V A y- / ^ ' • ' ' '' ''' • '.\ ’• ^\. < ' .' :.'‘ y V ' :,' i'^. "sjV'- ; -'- .' ; .; ^r-'\ ^ .;'^, ,' r -* ; , K;v.-^k:\i,;' ; 4?y. i V ' -V- - ,-v-y v; •; ^ ' . :v\‘' y .. y-tv'-'./y .• ^i,y;''f?^v•'•l^//t•:s;y•;^^ ?( ^ v |' • y ^:vyy y} i.) .' ' • - •.-'. - ? -k r-\- y 4 y; •^•/•v-vt>r- : ;A.y ' 7 '• • - • \ \ /n . Lv. 7 :'-.r '^C/rr^y V V- '•/’I 4 ’i 4:yyv4 ' ' fk i'y'' ^ ' y... V 4^ ,',vr.y 44v. -' Vi/ •^i' "•• -* ' ' ’ '- .'. ' : - ,.i fo. C, r , , ; 1 ; ’• ly .h.-' ANNUAL REPORTS OF THE OFFICERS AND DEPARTMENTS - A OF THE QTY OF ATTLEBORO ' * V FOR THE YEAR ^ 19 2 9 ATTLEBORO PRINT, Inc. ATTLEBORO, MASS. 1 ATTLEBORO PUBLIC LIBRARY 3 & 5 4 0 0l30304bb ANNUAL REPORTS OF THE OFFICERS AND DEPARTMENTS OF THE CITY OF ATTLEBORO FOR THE YEAR 19 2 9 ATTLEBORO PRINT, Inc. ATTLEBORO, MASS. ' Digitized by,the Internet Archive V .‘•‘ili'gQte ;* :[•: ij : T j https://archive.org/details/reportsoftownoff1929attl .1 666^6 ANNUAL KKl’ORT Government and Officers OF THE City of Attleboro FOR 1929 Mayor Fred E. Briggs Term expires January, 1931 Office open from 8:30 to 12:00 A. M., 1:30 to 5:00 P. M. daily and 8:30 to 12:00 A, M. Saturday. Councilmen-at Large William A. Brennan Arthur F. Gehrung Charles J. Merritt, President John A, Thayer H. Winslow Brown James L. Wiggmore Ward Councilmen Ward 1 G. Dallas Jencks Ward 2 Oscar F. Klinke VVard 3 Frank J.
    [Show full text]